Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

GSK, Vir’s COVID-19 mAb scores FDA emergency use approval

Interim phase 3 trial results found sotrovimab reduced the risk of hospitalisation or death by 85% compared to placebo

- PMLiVE

Q&A: Sarah Gordon

PME interviews Virgo Health's head of health

Digital Health for Improving Care in Disadvantaged Populations

Peter Wood (Co-founder & COO) and Dr. Raj Padwal (Co-founder & CEO) from mmHg Inc. explain how their Sphygmo virtual care system can be used to monitor blood pressure, glucose,...

Impetus Digital

The Future of Digital Pills

Valerie Sullivan, President and CEO at etectRx, dives into digital pills in healthcare and clinical research. Among many other things, we discuss how Pharma companies can benefit from the ability...

Impetus Digital

Improving Healthcare Access & Consumer Choice Through Digital Health

Erin Russell, Founder and CEO of Health Grizzly, shares her company’s approach to improving healthcare access and consumer choice through digital health. She also explores digital transformation in healthcare, how...

Impetus Digital

- PMLiVE

EU takes legal steps against AZ over delayed COVID-19 vaccine deliveries

Lawyers for the European Commission have asked the court to fine AZ €10m per infraction

- PMLiVE

Health Unlimited to acquire medcomms consultancy Strategen

Health Unlimited said the acquisition of Strategen will further strengthen its medical education services

- PMLiVE

Nicky Hutchens appointed as deputy managing director at Four Health

Hutchens initially joined Four Health in 2017 as an account director

- PMLiVE

Rare diseases: why they can be so difficult to identify

Symptoms shared with more common diagnoses can make it more difficult to spot underlying rare diseases

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

- PMLiVE

Sanofi, GSK begin enrolment for phase 3 COVID-19 vaccine study

Study will investigate two formulations targeting the Wuhan strain and the South African variant

- PMLiVE

Novartis, Molecular Partners launch global study of novel COVID-19 drug

Initial positive phase 1 study results found that the drug was safe and well tolerated, with no significant adverse events reported

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links